{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:41:37Z","timestamp":1792662097127,"version":"4.5.0"},"reference-count":44,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Novel benzodiazepines are increasingly detected in poisonings. Their relative toxicities remain poorly defined, complicating public health responses. Bromazolam has emerged in recent reports of severe poisoning. We sought a method to identify higher\u2010risk novel benzodiazepines, and to describe the clinical effects of bromazolam exposures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A prospective observational surveillance study examined time trends in laboratory\u2010confirmed detections of benzodiazepines of interest (novels plus alprazolam) using police drug seizure data and a clinical surveillance program from January 2019 to December 2024. A case series described hospitalised patients with confirmed bromazolam exposure between January 2022 and December 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Population\u2010based study in New South Wales, Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Cases<\/jats:title>\n                    <jats:p>All laboratory confirmed detections of benzodiazepines of interest in blood, urine or physical drug samples were included. Forty\u2010eight hospitalised patients with confirmed bromazolam exposure were included in the case series, and eight additional hospitalised patients with alprazolam exposures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>Annual detections of benzodiazepines of interest in clinical and physical drug samples were recorded. Relative toxicity was estimated with a pooled risk ratio (RR) of clinical to physical detections for each benzodiazepine. A minimum clinical dataset described the demographics, clinical effects, drug co\u2010detections, treatments and outcomes of bromazolam and alprazolam\u2010related hospital presentations. Secondary analyses measured the relationship between clinical effects and bromazolam blood concentrations and opioid co\u2010detection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median number of benzodiazepines of interest detected was 265\/year in physical drug samples (range 230\u2013301) and 16\/year in clinical samples (range 11\u201336). Bromazolam was the most common novel benzodiazepine detected in clinical (52\/118) and physical (382\/1590) samples. Pooled RRs were highest for etizolam [RR = 1.84, 95% confidence interval (95% CI) = 1.39\u20132.43], bromonordiazepam (RR = 1.70, 95% CI = 0.74\u20133.92), flualprazolam (RR = 1.48, 95% CI = 0.50\u20134.39) and bromazolam (RR = 1.22, 95% CI = 0.85\u20131.73). In 2024, there were no detections of etizolam or flualprazolam in clinical cases, compared with bromazolam (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200929; 80.6% of cases) and bromonordiazepam (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097; 19.4% of cases). Among the 48 hospital cases with bromazolam detected, severe outcomes were frequent, including coma (36\/48), respiratory failure (34\/48) and endotracheal intubation (25\/48). Polysubstance use was common (47\/48). Bromazolam blood concentrations were poorly predictive of clinical effects. Opioid co\u2010detection was not associated with statistically significantly worse outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The incidence of novel benzodiazepine detections in New South Wales, Australia, increased between January 2019 and December 2024. Bromazolam is a current concern due to increasing detections and severe clinical outcomes; however, polysubstance use likely contributed to clinical outcomes. Bromonordiazepam may be an emerging concern.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.70673","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:12:58Z","timestamp":1792660378000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting high\u2010risk novel benzodiazepines: A surveillance study of novel benzodiazepine detections and a case series of bromazolam exposures in New South Wales, Australia"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2854-4373","authenticated-orcid":false,"given":"Emily Z. G.","family":"Sansoni","sequence":"first","affiliation":[{"name":"Edith Collins Centre, Drug Health Services Royal Prince Alfred Hospital  Sydney Australia"},{"name":"New South Wales Poisons Information Centre Sydney Children's Hospital Network  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8896-1188","authenticated-orcid":false,"given":"Janette L.","family":"Smith","sequence":"additional","affiliation":[{"name":"Centre for Alcohol and Other Drugs, NSW Ministry of Health  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8203-4983","authenticated-orcid":false,"given":"Christine A.","family":"Harvey","sequence":"additional","affiliation":[{"name":"Centre for Alcohol and Other Drugs, NSW Ministry of Health  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4618-2102","authenticated-orcid":false,"given":"Vanessa","family":"Shaw","sequence":"additional","affiliation":[{"name":"Forensic Toxicology Laboratory, NSW Health Pathology, Forensic and Analytical Science Service  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6000-7946","authenticated-orcid":false,"given":"Christopher","family":"Ewers","sequence":"additional","affiliation":[{"name":"Illicit Drugs Analysis Unit, NSW Health Pathology, Forensic and Analytical Science Service  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8993-2693","authenticated-orcid":false,"given":"Ingrid","family":"Berling","sequence":"additional","affiliation":[{"name":"New South Wales Poisons Information Centre Sydney Children's Hospital Network  Sydney Australia"},{"name":"Department of Clinical Toxicology and Pharmacology Calvary Mater Newcastle  Newcastle Australia"},{"name":"School of Medicine and Public Health University of Newcastle  Newcastle Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-1939","authenticated-orcid":false,"given":"Thanjira","family":"Jiranantakan","sequence":"additional","affiliation":[{"name":"Edith Collins Centre, Drug Health Services Royal Prince Alfred Hospital  Sydney Australia"},{"name":"New South Wales Poisons Information Centre Sydney Children's Hospital Network  Sydney Australia"},{"name":"Centre for Alcohol and Other Drugs, NSW Ministry of Health  Sydney Australia"},{"name":"Faculty of Medicine and Health The University of Sydney  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6855-3865","authenticated-orcid":false,"given":"Jared","family":"Brown","sequence":"additional","affiliation":[{"name":"New South Wales Poisons Information Centre Sydney Children's Hospital Network  Sydney Australia"},{"name":"Centre for Alcohol and Other Drugs, NSW Ministry of Health  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-7577","authenticated-orcid":false,"given":"Darren M.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Edith Collins Centre, Drug Health Services Royal Prince Alfred Hospital  Sydney Australia"},{"name":"New South Wales Poisons Information Centre Sydney Children's Hospital Network  Sydney Australia"},{"name":"School of Clinical Medicine University of New South Wales  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104245"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14060560"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkag026"},{"key":"e_1_2_10_5_1","unstructured":"United Nations Office on Drugs and Crime.Current NPS threats [Internet]. Vienna Austria: United Nations;2024Jul [cited 2024 Nov 23]. Report Volume VII. Available from:https:\/\/www.unodc.org\/documents\/scientific\/Current_NPS_threats_VII.pdf"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2023.111891"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16520"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.14054"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2021.111140"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.70174"},{"key":"e_1_2_10_11_1","unstructured":"United Nations Office on Drugs and Crime. Current NPS threats [Internet].Vienna Austria: United Nations; 2025 Dec [cited 2026 Jun 26]. Report Volume 8. Available from:https:\/\/sway.cloud.microsoft\/fXvS1JLKczS64su6?ref=Link"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2025.112708"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkae079"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2025.2524078"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2026.105367"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2026.113085"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.70086"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.14068"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2025.2490831"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkad005"},{"key":"e_1_2_10_21_1","unstructured":"WHO Expert Committee on Drug Dependence.Bromazolam [Internet].2024[cited 2025 Dec 12]. Available from:https:\/\/ecddrepository.org\/en\/bromazolam"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108637"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.52638"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.26209"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja12.10986"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.2992"},{"key":"e_1_2_10_27_1","unstructured":"Therapeutic Goods Administration.Final decisions and reasons for decisions by delegates of the Secretary to the Department of Health and Ageing June 2013 [Internet]. Australian Capital Territory; 2013 [cited 2026 Jun 26]. Available from:https:\/\/www.tga.gov.au\/sites\/default\/files\/scheduling-decisions-1306-final.pdf"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02089.x"},{"key":"e_1_2_10_29_1","unstructured":"NSW Health.Prescription recreational and illicit substance evaluation (PRISE) summary program activity report [Internet]. St Leonards: NSW Ministry of Health; 2023. Available from:https:\/\/www.health.nsw.gov.au\/aod\/programs\/Publications\/prise-summary-report-2018-2021.pdf"},{"key":"e_1_2_10_30_1","unstructured":"New South Wales Government Department of Planning Housing and Infrastructure.2024 common planning assumptions population and dwelling predictions [Internet]. Parramatta: NSW Government; 2024. Available from: Not publicly available."},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scijus.2017.12.004"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000001071"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13052"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0310655"},{"key":"e_1_2_10_35_1","unstructured":"Expert Committee on Drug Dependence.Critical review report: bromazolam [Internet]. Geneva Switzerland: World Health Organization;2023[cited 2024 Nov 23]. Report 46th Meeting. p. 15. Available from:https:\/\/cdn.who.int\/media\/docs\/default\u2010source\/46th\u2010ecdd\/bromazolam_46th\u2010ecdd\u2010critical\u2010review_public\u2010version.pdf?sfvrsn=4f1bccfa_1"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkae074"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkae067"},{"key":"e_1_2_10_38_1","unstructured":"PapsunD KrotulskiA MastrovitoR WaltonS LoganB.Bromazolam prevalence surging across the United States driven in part by increasing detections alongside fentanyl [Internet]. Florida International University: Center for Forensic Science Research and Education; 2022 [cited 2025 Jul 31]. Available from:https:\/\/www.cfsre.org\/images\/content\/reports\/public_alerts\/Public\u2010Alert_Bromazolam_NPS\u2010Discovery_061522.pdf"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/1556-4029.70003"},{"key":"e_1_2_10_40_1","volume-title":"New benzodiazepines in Europe \u2010 a review","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2021"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02915-5"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkaa161"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.14057"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/01632780122034885"},{"key":"e_1_2_10_45_1","unstructured":"DeeksJ HigginsJ AltmanD McKenzieJ VeronikiA.Cochrane handbook for systematic reviews of interventions [Internet]. Version 6.5. Cochrane; 2024 [cited 2026 Jul 7]. Chapter 10: Analysing data and undertaking meta\u2010analyses. Available from:https:\/\/www.cochrane.org\/authors\/handbooks\u2010and\u2010manuals\/handbook\/current\/chapter\u201010"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.70673","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.70673","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.70673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:13:06Z","timestamp":1792660386000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.70673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":44,"alternative-id":["10.1111\/add.70673"],"URL":"https:\/\/doi.org\/10.1111\/add.70673","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"2026-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"add.70673"}}